drugset / Trial / NCT01153347

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01153347

Phase 3 Completed 2409 enrolled AstraZeneca Targacept Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.

Timeline

Start
2010-06
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject dexmecamylamine Other / unclassified 0.5 mg Oral
Subject dexmecamylamine Other / unclassified 2 mg Oral
Subject dexmecamylamine Other / unclassified 4 mg Oral